William P. Esler

William P. Esler

Auto-generated profile, based on publicly available information

William P. Esler

Internal Medicine Research Unit, Pfizer Research and Development, Pfizer Inc., Cambridge, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
RCRoberto A. Calle
Roberto A. Calle
NANeeta B. Amin
Neeta B. Amin
SCSantos Carvajal-Gonzalez
Santos Carvajal-Gonzalez
TRTrenton T. Ross
Trenton T. Ross
ABArthur Bergman
Arthur Bergman
WEWilliam P. Esler
William P. Esler

1 November 2007 in Endocrinology
Verified
Journal Article
Closed access
WEWilliam P. Esler
William P. Esler
JRJoachim Rudolph
Joachim Rudolph
TCThomas H. Claus
Thomas H. Claus
WTWeifeng Tang
Weifeng Tang
NBNicole Barucci
Nicole Barucci
LSLaurel J. Sweet
Laurel J. Sweet
Ghrelin, through action on its receptor, GH secretagogue receptor type 1a (GHS-R1a), exerts a variety of metabolic functions including stimulation of appetite and weight gain and suppression of insulin secretion. In the present study, we examined the effects of novel small-molecule GHS-R1a antagonists on insulin secretion, glucose tolerance, and weight loss. Ghrelin dose-dependently suppressed insulin secretion from dispersed rat islets. This effect was fully blocked by a GHS-R1a antagonist. Consistent with this observation, a single oral dose of a GHS-R1a antagonist improved glucose homeostasis in an ip glucose tolerance test in rat. Improvement in glucose tolerance was attributed to increased insulin secretion. Daily oral administration of a GHS-R1a antagonist to diet-induced obese mice led to reduced food intake and weight loss (up to 15%) due to selective loss of fat mass. Pair-feeding experiments indicated that weight loss was largely a consequence of reduced food intake. The impact of a GHS-R1a antagonist on gastric emptying was also examined. Although the GHS-R1a antagonist modestly delayed gastric emptying at the highest dose tested (10 mg/kg), delayed gastric emptying does not appear to be a requirement for weight loss because lower doses produced weight loss without an effect on gastric emptying. Consistent with the hypothesis that ghrelin regulates feeding centrally, the anorexigenic effects of potent GHS-R1a antagonists in mice appeared to correspond with their brain exposure. These observations demonstrate that GHS-R1a antagonists have the potential to improve the diabetic condition by promoting glucose-dependent insulin secretion and promoting weight loss.

15 November 2023 in Journal of Hepatology
Verified
Journal Article
Closed access
WEWilliam P. Esler
William P. Esler
DCDavid E. Cohen
David E. Cohen

12 January 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JJJessica E. C. Jones
Jessica E. C. Jones
WEWilliam P. Esler
William P. Esler
RPRushi Patel
Rushi Patel
ALAdhiraj Lanba
Adhiraj Lanba
NVNicholas B. Vera
Nicholas B. Vera
CVCecile Vernochet
Cecile Vernochet
Tumor cell proliferation and migration processes are regulated by multiple metabolic pathways including glycolysis and de novo lipogenesis. Since acetyl-CoA carboxylase (ACC) is at the junction of lipids synthesis and oxidative metabolic pathways, we investigated whether use of a dual ACC inhibitor would provide a potential therapy against certain lipogenic cancers. The impact of dual ACC1/ACC2 inhibition was investigated using a dual ACC1/ACC2 inhibitor as well as dual siRNA knock down on the cellular viability and metabolism of two glioblastoma multiform cancer cell lines, U87 and a more aggressive form, U87 EGFRvIII. We first demonstrated that while ACCi inhibited DNL in both cell lines, ACCi preferentially blunted the U87 EGFRvIII cellular proliferation capacity. Metabolically, chronic treatment with ACCi significantly upregulated U87 EGFRvIII cellular respiration and extracellular acidification rate, a marker of glycolytic activity, but impaired mitochondrial health by reducing maximal respiration and decreasing mitochondrial ATP production efficiency. Moreover, ACCi treatment altered the cellular lipids content and increased apoptotic caspase activity in U87 EGFRvIII cells. Collectively these data indicate that ACC inhibition, by reducing DNL and increasing cellular metabolic rate, may have therapeutic utility for the suppression of lipogenic tumor growth and warrants further investigation.

1 January 2020 in Cellular and Molecular Gastroenterology and Hepatology
Verified
Journal Article
Open access
TRTrenton T. Ross
Trenton T. Ross
CCCollin Crowley
Collin Crowley
KKKenneth L. Kelly
Kenneth L. Kelly
ARAnthony Rinaldi
Anthony Rinaldi
DBDavid A. Beebe
David A. Beebe
WEWilliam P. Esler
William P. Esler
Disordered metabolism, steatosis, hepatic inflammation, and fibrosis contribute to the pathogenesis of nonalcoholic steatohepatitis (NASH). Acetyl-CoA carboxylase (ACC) catalyzes the first committed step in de novo lipogenesis (DNL) and modulates mitochondrial fatty acid oxidation. Increased hepatic DNL flux and reduced fatty acid oxidation are hypothesized to contribute to steatosis. Some pro-inflammatory cells also show increased dependency on DNL, suggesting that ACC may regulate aspects of the inflammatory response in NASH. PF-05221304 is an orally bioavailable, liver directed ACC1/2 inhibitor. The present studies sought to evaluate the effects of PF-05221304 on NASH pathogenic factors in experimental model systems. The effects of PF-05221304 on lipid metabolism, steatosis, inflammation and fibrogenesis were interrogated in both primary human derived in vitro systems and in vivo rodent models. PF-05221304 inhibited DNL, stimulated fatty acid oxidation and reduced triglyceride accumulation in primary human hepatocytes, and reduced DNL and steatosis in western diet fed rats in vivo, demonstrating potential to reduce hepatic lipid accumulation and potentially lipotoxicity. PF-05221304 blocked polarization of human T-cells to pro-inflammatory but not anti-inflammatory T-cells and suppressed activation of primary human stellate cells to myofibroblasts in vitro, demonstrating direct effects on inflammation and fibrogenesis. Consistent with these observations, PF-05221304 also reduced markers of inflammation and fibrosis in the diethylnitrosamine chemical induced liver injury model and the choline deficient high-fat fed rat model. The liver directed dual ACC1/ACC2 inhibitor directly improved multiple NAFLD/NASH pathogenic factors including steatosis, inflammation and fibrosis in both human derived in vitro systems and rat models.

1 June 2021 in Molecular Metabolism
Verified
Journal Article
Open access
JGJemy A. Gutierrez
Jemy A. Gutierrez
WLWei Liu
Wei Liu
SPSylvie Perez
Sylvie Perez
GXGang Xing
Gang Xing
GSGabriele Sonnenberg
Gabriele Sonnenberg
GTGregory J. Tesz
Gregory J. Tesz
Recent studies suggest that excess dietary fructose contributes to metabolic dysfunction by promoting insulin resistance, de novo lipogenesis (DNL), and hepatic steatosis, thereby increasing the risk of obesity, type 2 diabetes (T2D), non-alcoholic steatohepatitis (NASH), and related comorbidities. Whether this metabolic dysfunction is driven by the excess dietary calories contained in fructose or whether fructose catabolism itself is uniquely pathogenic remains controversial. We sought to test whether a small molecule inhibitor of the primary fructose metabolizing enzyme ketohexokinase (KHK) can ameliorate the metabolic effects of fructose. The KHK inhibitor PF-06835919 was used to block fructose metabolism in primary hepatocytes and Sprague Dawley rats fed either a high-fructose diet (30% fructose kcal/g) or a diet reflecting the average macronutrient dietary content of an American diet (AD) (7.5% fructose kcal/g). The effects of fructose consumption and KHK inhibition on hepatic steatosis, insulin resistance, and hyperlipidemia were evaluated, along with the activation of DNL and the enzymes that regulate lipid synthesis. A metabolomic analysis was performed to confirm KHK inhibition and understand metabolite changes in response to fructose metabolism in vitro and in vivo. Additionally, the effects of administering a single ascending dose of PF-06835919 on fructose metabolism markers in healthy human study participants were assessed in a randomized placebo-controlled phase 1 study. Inhibition of KHK in rats prevented hyperinsulinemia and hypertriglyceridemia from fructose feeding. Supraphysiologic levels of dietary fructose were not necessary to cause metabolic dysfunction as rats fed the American diet developed hyperinsulinemia, hypertriglyceridemia, and hepatic steatosis, which were all reversed by KHK inhibition. Reversal of the metabolic effects of fructose coincided with reductions in DNL and inactivation of the lipogenic transcription factor carbohydrate response element-binding protein (ChREBP). We report that administering single oral doses of PF-06835919 was safe and well tolerated in healthy study participants and dose-dependently increased plasma fructose indicative of KHK inhibition. Fructose consumption in rats promoted features of metabolic dysfunction seen in metabolic diseases such as T2D and NASH, including insulin resistance, hypertriglyceridemia, and hepatic steatosis, which were reversed by KHK inhibition.